Edit

Amporin Pharmaceuticals AG

https://www.amporin.com/

Amporin Pharmaceuticals AG is a Swiss biotech company based in Basel and founded in 2024 by a small team of industry-seasoned drug development experts. We are developing a breakthrough new class of small molecule drugs that can protect and repair cell membranes as the first potential acute oral disease-modifying treatments for multiple deadly degenerative diseases associated with protein misfolding and aggregation, including Alzheimer's, Parkinson's, type II diabetes, and more than 50 rare degenerative diseases. Together, these diseases affect over half a billion people and kill 3.6 million people around the world each year, at a total cost to society of USD 3 trillion per year, with no effective treatments that can stop or reverse the progression of disease. By directly targeting the fundamental molecular process which causes all these diseases, our vision is to cure 6 deadly degenerative diseases with a simple pill, starting with Parkinson’s disease and ALS. Amporin won 3rd place in the Venture.ch Swiss national startup business plan competition, and recently won the final stage of Venture Kick. https://www.venture.ch/venture-winners-2/amporin-pharmaceuticals https://www.venturekick.ch/Amporin-Pharmaceuticals-receives-the-CHF-150000-Kick-to-develop-a-breakthrough-class-of-smallmolecule-drugs